The activating BRAF V600E mutation has been successfully targeted with dual molecular therapy in melanoma, non–small cell lung carcinoma (NSCLC), and thyroid cancer. BRAF V600E mutations have also been identified in a subset of patients with pediatric and adult brain tumors, and several case reports have indicated the potential efficacy of targeted therapy in these patients. To date, these studies have mostly been performed using single-agent BRAF inhibitor therapy in recurrent low-grade gliomas (LGGs; Table 1). This report describes the use of combination dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in 2 adults with high-grade gliomas (HGGs). The first patient was treated at time of diagnosis, whereas the second was treated at time of recurrence in conjunction with the antiangiogenic agent bevacizumab. Both patients showed rapid and dramatic clinical and radiographic responses.
Dr. Ansstas has disclosed that he is a member of the advisory board and speaker's bureau for Novocure. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Drs. Johanns and Grierson are supported by the NIH T32 HL007088 training grant through the Division of Hematology and Physician-Scientist Training Program at Washington University School of Medicine.
Alexandrescu S, Korshunov A, Lai SH et al.. Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas—same entity or first cousins? Brain Pathol 2016;26:215–223.
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–690.
Landa I, Ibrahimpasic T, Boucai L et al.. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016;126:1052–1066.
Behling F, Barrantes-Freer A, Skardelly M et al.. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol 2016;11:55.
Schindler G, Capper D, Meyer J et al.. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397–405.
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330–337.
Chen D, Zhang LQ, Huang JF et al.. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2014;9:e101354.
Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576–582.
Pickering CR, Zhang J, Yoo SY et al.. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 2013;3:770–781.
Louis DN, Perry A, Reifenberger G et al.. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–820.
Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013;37:685–698.
Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 2014;14:258.
Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol 2015;39:528–540.
Chi AS, Batchelor TT, Yang D et al.. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013;31:e233–236.
Lee D, Cho YH, Kang SY et al.. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. J Surg Oncol 2015;111:359–364.
Chappe C, Padovani L, Scavarda D et al.. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 2013;23:574–583.
Dahiya S, Haydon DH, Alvarado D et al.. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013;125:901–910.
Dougherty MJ, Santi M, Brose MS et al.. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010;12:621–630.
Matsumura N, Nakajima N, Yamazaki T et al.. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma. Neuropathology 2017;37:58–63.
Tanaka S, Nakada M, Nobusawa S et al.. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. Brain Tumor Pathol 2014;31:172–176.
Nobusawa S, Hirato J, Kurihara H et al.. Intratumoral heterogeneity of genomic imbalance in a case of epithelioid glioblastoma with BRAF V600E mutation. Brain Pathol 2014;24:239–246.
Kuroda J, Nobusawa S, Nakamura H et al.. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma. Neuropathology 2016;36:181–186.
Funata N, Nobusawa S, Yamada R, Shinoura N. A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation. Brain Tumor Pathol 2016;33:57–62.
Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol 2013;114:237–240.
Gierke M, Sperveslage J, Schwab D et al.. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. J Cancer Res Clin Oncol 2016;142:89–100.
Korshunov A, Meyer J, Capper D et al.. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009;118:401–405.
Korshunov A, Ryzhova M, Hovestadt V et al.. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 2015;129:669–678.
Bautista F, Paci A, Minard-Colin V et al.. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 2014;61:1101–1103.
Usubalieva A, Pierson CR, Kavran CA et al.. Primary meningeal pleomorphic xanthoastrocytoma with anaplastic features: a report of 2 cases, one with BRAF(V600E) mutation and clinical response to the BRAF inhibitor dabrafenib. J Neuropathol Exp Neurol 2015;74:960–969.
Skrypek M, Foreman N, Guillaume D, Moertel C. Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer 2014;61:2099–2100.
Aguilera D, Janss A, Mazewski C et al.. Successful retreatment of a child with a refractory brainstem ganglioglioma with vemurafenib. Pediatr Blood Cancer 2016;63:541–543.
del Bufalo F, Carai A, Figa-Talamanca L et al.. Response of recurrent BRAFV600E mutated ganglioglioma to vemurafenib as single agent. J Transl Med 2014;12:356.
Lassaletta A, Guerreiro Stucklin A, Ramaswamy V et al.. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. Pediatr Blood Cancer 2016;63:2038–2041.
Meletath SK, Pavlick D, Brennan T et al.. Personalized treatment for a patient with a BRAF V600E mutation using dabrafenib and a tumor treatment fields device in a high-grade glioma arising from ganglioglioma. J Natl Compr Canc Netw 2016;14:1345–1350.
Lee EQ, Ruland S, LeBoeuf NR et al.. Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy. J Clin Oncol 2016;34:e87–89.
Long GV, Stroyakovskiy D, Gogas H et al.. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444–451.
Larkin J, Ascierto PA, Dreno B et al.. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867–1876.